Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates

No abstract is available for this paper.

• Publication year

  2017

• Venue

  mAbs

• Publication date

  2017-06-08

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1080/19420862.2017.1323160PMID 28463063PMCID PMC5524161
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.

  2016cited by this paper
• Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies

  2016cited by this paper
• Target-independent variable region mediated effects on antibody clearance can be FcRn independent

  2016cited by this paper
• High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice

  2015cited by this paper
• The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity

  2015cited by this paper
• Conformational Destabilization of Immunoglobulin G Increases the Low pH Binding Affinity with the Neonatal Fc Receptor*

  2015cited by this paper
• The therapeutic monoclonal antibody market

  2015cited by this paper
• Therapeutic antibodies: Discovery, design and deployment.

  2015cited by this paper
• A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life

  2015cited by this paper
• Developability assessment during the selection of novel therapeutic antibodies.

  2015cited by this paper
• Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics*

  2015cited by this paper
• Antibody engineering for increased potency, breadth and half-life

  2015cited by this paper
• Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics

  2015cited by this paper
• Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics

  2015influential reference
• Next-generation optimized biotherapeutics - A review and preclinical study.

  2014cited by this paper
• In silico selection of therapeutic antibodies for development: Viscosity, clearance, and chemical stability

  2014cited by this paper
• Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody

  2014cited by this paper
• Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies.

  2014cited by this paper
• Biologics: an update and challenge of their pharmacokinetics.

  2014cited by this paper
• Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity

  2013influential reference
• Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies

  2013cited by this paper
• An automated immunoassay for early specificity profiling of antibodies

  2013cited by this paper
• Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool.

  2013cited by this paper
• Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities

  2013cited by this paper
• Alpha thalassaemia and extended alpha globin genes in Sri Lanka.

  2013cited by this paper
• Developability studies before initiation of process development

  2013cited by this paper
• Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?

  2013cited by this paper
• Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies

  2013cited by this paper
• Production, characterization and pharmacokinetic properties of antibodies with N-linked Mannose-5 glycans

  2012cited by this paper
• FcRn Affinity-Pharmacokinetic Relationship of Five Human IgG4 Antibodies Engineered for Improved In Vitro FcRn Binding Properties in Cynomolgus Monkeys

  2012cited by this paper
• Discovery pharmacokinetic studies in mice using serial microsampling, dried blood spots and microbore LC-MS/MS.

  2012cited by this paper
• ADME of Biologics—What Have We Learned from Small Molecules?

  2012cited by this paper
• Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.

  2012cited by this paper
• A strategy for risk mitigation of antibodies with fast clearance

  2012cited by this paper
• Complex Pharmacokinetics of a Humanized Antibody Against Human Amyloid Beta Peptide, Anti-Abeta Ab2, in Nonclinical Species

  2011cited by this paper
• Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data

  2011cited by this paper
• Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential

  2011cited by this paper
• Monoclonal Antibodies with Identical Fc Sequences Can Bind to FcRn Differentially with Pharmacokinetic Consequences

  2011cited by this paper
• Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4

  2011cited by this paper
• Quantitative Prediction of Human Pharmacokinetics for Monoclonal Antibodies

  2011cited by this paper
• Efficient production of antibodies against a mammalian integral membrane protein by phage display.

  2011cited by this paper
• Computational Docking of Antibody-Antigen Complexes, Opportunities and Pitfalls Illustrated by Influenza Hemagglutinin

  2011cited by this paper
• Prediction of human pharmacokinetics of therapeutic monoclonal antibodies from simple allometry of monkey data.

  2011cited by this paper
• Neonatal Fc Receptor: From Immunity to Therapeutics

  2010cited by this paper
• Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis.

  2010cited by this paper
• In vitro potency, pharmacokinetic profiles and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus

  2010cited by this paper
• Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies.

  2010cited by this paper
• Reduced elimination of IgG antibodies by engineering the variable region.

  2010cited by this paper
• Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents

  2010cited by this paper
• Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited

  2010cited by this paper
• Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

  2010cited by this paper
• A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life.

  2010influential reference
• Construction, MD simulation, and hydrodynamic validation of an all-atom model of a monoclonal IgG antibody.

  2010cited by this paper
• Briakinumab

  2009cited by this paper
• Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL‐12/23p40, in Patients With Moderate to Severe Plaque Psoriasis

  2009cited by this paper
• Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations

  2009cited by this paper
• Pharmacokinetic applications of microdevices and microsampling techniques.

  2009cited by this paper
• Interspecies Scaling of Therapeutic Monoclonal Antibodies: Initial Look

  2009cited by this paper
• Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates

  2009cited by this paper
• Binding of Matrix Metalloproteinase Inhibitors to Extracellular Matrix: 3D‐QSAR Analysis

  2008cited by this paper
• Determination and validation of off-target activities of anti-CD44 variant 6 antibodies using protein biochips and tissue microarrays.

  2008cited by this paper
• Humanized IgG1 Variants with Differential Binding Properties to the Neonatal Fc Receptor: Relationship to Pharmacokinetics in Mice and Primates

  2007cited by this paper
• Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.

  2007cited by this paper
• Monoclonal Antibody Clearance

  2007cited by this paper
• An Engineered Human IgG1 Antibody with Longer Serum Half-Life

  2006cited by this paper
• Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)*

  2006cited by this paper
• Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.

  2006cited by this paper
• Conferring the binding properties of the mouse MHC class I-related receptor, FcRn, onto the human ortholog by sequential rounds of site-directed mutagenesis.

  2005influential reference
• The sweet and sour of cancer: glycans as novel therapeutic targets

  2005cited by this paper
• Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates*

  2004cited by this paper
• A good practice guide to the administration of substances and removal of blood, including routes and volumes

  2001cited by this paper
• The Fab and Fc fragments of IgA1 exhibit a different arrangement from that in IgG: a study by X-ray and neutron solution scattering and homology modelling.

  1999cited by this paper
• Functions of cell surface heparan sulfate proteoglycans.

  1999cited by this paper
• Comparative studies of rat IgG to further delineate the Fc  :  FcRn interaction site

  1998cited by this paper
• Antibody structure, prediction and redesign.

  1997cited by this paper
• Increasing the serum persistence of an IgG fragment by random mutagenesis

  1997influential reference

• Nonspecific Cellular Interactions Are a Key Determinant in the Disposition of Fc-Fused Proteins.

  2026cites this paper
• A transposon-based transient transfection system in CHO-K1 cells enables quality prediction of stable cell line proteins

  2025cites this paper
• Isoelectric point, net charge and amino acid analysis of experimentally validated therapeutic antibodies.

  2025cites this paper
• "Assessing Impact of Hinge Flexibility on Predicted Second Osmotic Virial Coefficients".

  2025cites this paper
• Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows

  2024cites this paper
• Human antibody polyreactivity is governed primarily by the heavy-chain complementarity-determining regions

  2024cites this paper
• Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn

  2024cites this paper
• Physiologically Based Pharmacokinetic Modeling to Characterize the Effect of Molecular Charge on Whole-Body Disposition of Monoclonal Antibodies

  2023cites this paper
• The origins of nonideality exhibited by monoclonal antibodies and Fab fragments in human serum

  2023cites this paper
• Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice

  2023cites this paper
• Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework

  2023cites this paper
• Surface patches induce nonspecific binding and phase separation of antibodies

  2023cites this paper
• Embedding Dynamics in Intrinsic Physicochemical Profiles of Market-Stage Antibody-Based Biotherapeutics

  2022cites this paper
• Special Section on Pharmacokinetics and ADME of Biological Therapeutics — Minireview Characterizing the Pharmacokinetics and Biodistribution of Therapeutic Proteins: An Industry White Paper

  2022cites this paper
• Surface interaction patches link non-specific binding and phase separation of antibodies

  2022cites this paper
• Non-specificity as the sticky problem in therapeutic antibody development

  2022cites this paper
• Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper

  2022influential citation
• Microphysiological endothelial models to characterize subcutaneous drug absorption.

  2022cites this paper
• Characterizing the Pharmacokinetics and Biodistribution of Therapeutic Proteins: An Industry White Paper

  2022cites this paper
• ADME of Biologicals and New Therapeutic Modalities

  2021cites this paper
• Improving antibody drug development using bionanotechnology.

  2021cites this paper
• Novel In Vivo and In Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab.

  2021cites this paper
• Combination of cassette-dosing and microsampling for reduced animal usage for antibody pharmacokinetics in cynomolgus monkeys, wild-type mice, and human FcRn transgenic mice

  2021cites this paper
• A cell based assay for evaluating binding and uptake of an antibody using hepatic nonparenchymal cells

  2021cites this paper
• Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings

  2021cites this paper
• Interaction with 2,4-dinitrophenol correlates with polyreactivity, self-binding, and stability of clinical-stage therapeutic antibodies.

  2021cites this paper
• Toward Drug-Like Multispecific Antibodies by Design

  2020cites this paper
• Functional humanization of immunoglobulin heavy constant gamma 1 Fc domain human FCGRT transgenic mice

  2020cites this paper
• Harnessing the Therapeutic Potential of 'Rogue' Antibodies.

  2020cites this paper
• Pharmacokinetic prediction of an antibody in mice based on an in vitro cell-based approach using target receptor-expressing cells

  2020cites this paper
• Structure, heterogeneity and developability assessment of therapeutic antibodies

  2019cites this paper
• Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974.

  2019cites this paper
• Monoclonal Antibodies: From Structure to Therapeutic Application

  2019cites this paper
• Use of Cryopreserved Hepatocytes as Part of an Integrated Strategy to Characterize In Vivo Clearance for Peptide-Antibody Conjugate Inhibitors of Nav1.7 in Preclinical Species

  2019cites this paper
• Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development

  2018cites this paper
• Phenotypic Screening: The Function-FIRST Antibody Discovery Platform (F.I.R.S.TTM)

  2018cites this paper
• Survey Based Study to Assess the Principles, Assumptions, and Processes in Establishing Biologics Assets as a Fast to FIH (First-In-Human)

  2018cites this paper
• Principles, Assumptions, and Processes Established to Designate Biologics Assets as a Fast to FIH (First-in-Human) Program and the Associated Core Concepts for the Utilization of low and High-Risk Activities, Timelines and Functional Level Expectations

  2018cites this paper
• Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility.

  2018cites this paper
• Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics

  2018cites this paper
• Toward a Combinatorial Approach for the Prediction of IgG Half-Life and Clearance

  2018cites this paper
• Next generation antibody drugs: pursuit of the 'high-hanging fruit'

  2017cites this paper